TVGN vs. ADPT, PSTX, AVXL, RLAY, SANA, IMTX, REPL, CGEM, LENZ, and AUTL
Should you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Adaptive Biotechnologies (ADPT), Poseida Therapeutics (PSTX), Anavex Life Sciences (AVXL), Relay Therapeutics (RLAY), Sana Biotechnology (SANA), Immatics (IMTX), Replimune Group (REPL), Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), and Autolus Therapeutics (AUTL). These companies are all part of the "biological products, except diagnostic" industry.
Tevogen Bio vs.
Adaptive Biotechnologies (NASDAQ:ADPT) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
Adaptive Biotechnologies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -1.22, indicating that its stock price is 222% less volatile than the S&P 500.
Tevogen Bio has lower revenue, but higher earnings than Adaptive Biotechnologies.
Tevogen Bio has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -110.13%. Adaptive Biotechnologies' return on equity of -62.06% beat Tevogen Bio's return on equity.
Adaptive Biotechnologies currently has a consensus target price of $6.75, suggesting a potential downside of 7.29%. Tevogen Bio has a consensus target price of $4.20, suggesting a potential upside of 224.32%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Adaptive Biotechnologies.
Adaptive Biotechnologies received 94 more outperform votes than Tevogen Bio when rated by MarketBeat users. However, 100.00% of users gave Tevogen Bio an outperform vote while only 57.58% of users gave Adaptive Biotechnologies an outperform vote.
99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 56.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Tevogen Bio. MarketBeat recorded 2 mentions for Adaptive Biotechnologies and 1 mentions for Tevogen Bio. Adaptive Biotechnologies' average media sentiment score of 0.54 beat Tevogen Bio's score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.
Summary
Adaptive Biotechnologies beats Tevogen Bio on 8 of the 15 factors compared between the two stocks.
Get Tevogen Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tevogen Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TVGN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free TVGN Stock Alerts